NHS England offers groundbreaking blood cancer therapy

A groundbreaking "Trojan horse" cancer therapy, which delivers toxic drugs directly into cancer cells, will be available on the NHS in England, offering significantly extended remission for blood cancer patients. This marks a world first. The new treatment, belantamab mafodotin, targets myeloma, a blood cancer, and has shown to halt the disease for three years, nearly tripling the duration compared to existing therapies. The therapy minimizes side effects by delivering chemotherapy directly to cancer cells. The NHS decision follows positive clinical trials and a cost-effectiveness review. The therapy, developed in the UK, is expected to benefit around 1,500 patients annually, offering a potentially life-changing improvement in their quality of life.